Yueting Zhang^1,2, Sawitri Assanangkornchai², Wit Wichaidit^2,*

International Journal of Mental Health Promotion, Vol.28, No.6, 2026, DOI:10.32604/ijmhp.2026.079559 - 23 June 2026

Abstract Background: Stigma affects the mental well-being of cancer survivors. However, data are scarce regarding the extent to which specific types of stigmas, enacted stigma (stigma from others), and self-stigma (internalized stigma), affect mental well-being. The objective of this study is to describe the extent to which overall illness-related stigma, self-stigma, and enacted stigma are associated with mental well-being among cancer survivors. Methods: A cross-sectional study in Kunming, Yunnan, China, was conducted. Eligible participants were adult cancer survivors who completed a phone-to-WeChat, self-administered survey. Illness-related stigma was measured with the Stigma Scale for Chronic Illnesses, 8-item version… More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.086727 - 16 June 2026

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.086722 - 16 June 2026

Abstract This article has no abstract. More >

Liang Li^1,#, Huijuan Liu^1,#, Lianjiang Du², Pan Xi¹, Qian Wang¹, Yanqin Li³, Di Liu^4,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.086717 - 16 June 2026

Abstract This article has no abstract. More >

Raquel Sanchez-Baltasar¹, Nerea Castañeda-Fernández¹, Jorge Olivares-Arancibia², Carlos Torres-Villar^3,4, Julio Plaza-Diaz^5,6,7,8,*, Lourdes Herrera-Quintana^1,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.081924 - 16 June 2026

Abstract Breast cancer (BC) is the most frequently diagnosed malignancy in women worldwide and remains one of the leading causes of cancer-related mortality, with substantial international disparities in incidence, stage at diagnosis, access to treatment, and survival. In recent years, BC management has evolved rapidly through advances in molecular characterization, imaging, pathology, targeted therapies, immunotherapy, and survivorship care. Nevertheless, important gaps persist in early and accurate detection, biomarker standardization, equitable access to care, and patient-specific treatment selection. These advances require timely, evidence-based, and context-specific clinical frameworks to support appropriate implementation, and to avoid the use of… More >

Zhengzheng Li^1,2,#, Haitong Xie^1,2,#, Yujuan Chen^1,2, Qiuyan Li³, Xing Yuan⁴, Xinyue Dai³, Jie Chen^1,2,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.081209 - 16 June 2026

Abstract Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies. Phosphoglycerate kinase 1 (PGK1) drives TNBC progression, but mechanisms governing its protein stability remain unclear. This study aims to identify the E3 ubiquitin ligase responsible for PGK1 degradation and evaluate its therapeutic potential against metastasis. Methods: Clinical datasets and 50 human TNBC tissues were analyzed via multiplex immunohistochemistry. Co-immunoprecipitation, ubiquitination linkage assays, and structural modeling were utilized for in vitro mechanistic studies in TNBC cells. Additionally, functional impacts on epithelial-mesenchymal transition (EMT) and metastasis were evaluated using transwell assays and an in vivo mouse lung metastasis… More >

Yu-Hao Huang^1,#, Hao-Yeh Chen^2,#, Peng-Ju Chien¹, Chun-Yu Chen^2,3, Shao-Ti Li⁴, Hsueh-Te Lee⁵, Yueh-Chun Lee^4,6,*, Wen-Wei Chang^1,7,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.080978 - 16 June 2026

Abstract Backgrounds: Triple-negative breast cancer (TNBC) is highly aggressive, insensitive to radiotherapy, and exhibits increased cancer stem cell (CSC) properties, contributing to poor patient outcomes. B-cell lymphoma 2 (BCL2) associated transcription factor 1 (BCLAF1) is an oncogene in certain cancers, but its role in TNBC is unclear. This study investigated BCLAF1’s involvement in radioresistance and CSC activity in TNBC. Methods: BCLAF1 expression and clinical significance were analyzed using The Cancer Genome Atlas (TCGA) breast cancer dataset. Radioresistant MDA-MB-231 cells were used to examine BCLAF1’s function. Proto-oncogene SRC (SRC) overexpression, BCLAF1 knockdown, dasatinib treatment, and hypoxia inducible factor 1 subunit… More >

Zhen Wang¹, Qian Xie², Yu Luo³, Chuan Li¹, Wenqiang Guan¹, Yanling Zhang⁴, Jidong Miao^1,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.079813 - 16 June 2026

Abstract Objective: This study assesses peripheral blood parameters as predictors of programmed cell death protein-1 (PD-1) inhibitor efficacy in advanced non-small cell lung cancer (NSCLC). Methods: We retrospectively analyzed 169 advanced NSCLC patients receiving first-line PD-1 inhibitor-based therapy. Baseline blood parameters and clinical characteristics were recorded. Logistic regression assessed associations with immune-related adverse events (irAEs). Chi-square tests compared efficacy and safety across treatment groups. Results: Baseline albumin/fibrinogen ratio (ALB/FIB) and PIV were associated with all-grade irAEs (p < 0.05), while PIV was markedly associated with grade ≥3 irAEs (p < 0.01). Multivariate analysis identified that the baseline pan-immune inflammation More >

Ye Ri Han^1,*, Sang Bong Lee^2,3,4,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.079556 - 16 June 2026

Abstract Colorectal cancer liver metastasis (CRLM) remains a leading cause of cancer-related mortality, with clinical outcomes limited by biological heterogeneity and inconsistent therapeutic responses. Despite advances in systemic chemotherapy, targeted agents, immunotherapy, and liver-directed interventions, the translation of preclinical efficacy into clinical benefit remains suboptimal, highlighting the need for predictive experimental models. However, therapeutic efficacy in CRLM is highly model-dependent, and discrepancies between preclinical findings and clinical outcomes often arise from differences in biological fidelity across experimental platforms. This review critically examines preclinical platforms used to study CRLM, with emphasis on orthotopic and metastatic models that More >

Yangyang Zhang^1,2,3,#, Ilyar Mamtili^4,#, Yonghao Chen⁵, Guangjie Ji^1,2,3,*, Chaozhao Liang^1,2,3,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.079316 - 16 June 2026

Abstract Background: Prostate cancer (PCa) responds poorly to immunotherapy. We investigated the myeloid checkpoint TIM3 (HAVCR2) to define its lineage localization and regulatory logic in the PCa microenvironment. Methods: We integrated stage-resolved public single-cell RNA-seq datasets spanning primary PCa, metastatic hormone-sensitive PCa, and castration-resistant PCa. Myeloid compartments were analyzed via differential expression, regulon inference, and ligand–receptor modeling. Clinical relevance was evaluated in the Cancer Genome Atlas prostate adenocarcinoma (TCGA-PRAD) cohort and independent cohorts using a myeloid TIM3 signature. Mechanistic validation was achieved through PR domain zinc finger protein 1 (PRDM1) chromatin immunoprecipitation followed by Chromatin Immunoprecipitation (ChIP)–qPCR… More >